Results 101 to 110 of about 13,127 (167)

Assessment of the potential interactions between favipiravir and radiocontrast agents

BACKGROUND In cases of coronavirus disease 2019 ( COVID- 19), favipiravir is commonly included to the therapy regimen. Drug interactions between favipiravir and other COVID-19 therapy drugs are frequently researched. However, no research on possible drug
BARUN, SÜREYYA, Aydemir, Huseyin, Yazar, Mesut Furkan, AYDIN, SONAY, Kantarci, Mecit, Aydin, Ozlem Celik   +5 more
core   +1 more source

Pulmonary toxicity associated with high-dose favipiravir and treatment options: biochemical and histopathological evaluation Toxicidad pulmonar asociada a altas dosis de favipiravir y opciones de tratamiento: Evaluación bioquímica e histopatológica

Favipiravir is a broad-spectrum antiviral drug that is a viral RNA-dependent RNA polymerase inhibitor. Favipiravir is used in high doses to treat COVID-19 but has a side effect on humans at high doses. The side effects of favipiravir have been associated
MAMMADOV, RENAD, Yavuzer, Bulent, SÜLEYMAN, HALİS, SÜLEYMAN, BAHADIR, Elma, Bekir, ALTUNER, DURDU, ÜNVER, EDHEM, Mokhtare, Behzad, ÇOBAN, TAHA ABDULKADİR   +8 more
core   +1 more source

Lethal C57BL/6 mouse model for Yezo virus infection and antiviral therapeutic evaluation. [PDF]

Emerg Microbes Infect
Liu Y, Liu N, Zhang G, Liu Z, Ji T, Li L, Wang Z.   +6 more
europepmc   +1 more source

Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza

, 2018
Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients.
Regenerative Medicine and Stem Cells, Brain, Apotheek Opleiding, Murk, Jean-Luc, Nijstad, A Laura, MMB Medische Staf, Infection & Immunity, Apotheek Klinische Farmacie, Favié, Laurent Ma, van Maarseveen, Erik M, Medische Staf Intensive Care, Sikma, Maaike A, Meijer, Adam, Child Health   +13 more
core  

Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1). [PDF]

Virus Res
Arnold L, Schwarz V, Knoll G, Gessner A, Schmidt B, Bauswein M.   +5 more
europepmc   +1 more source

The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19. [PDF]

ERJ Open Res
Wawman RE, Shah PL, Boffito M, Tonkin J, Conway F, Tana A, Santos BR, Grinsztejn B, Crabtree Ramírez B, Pertinez H, Owen A, Curley P, Arshad U, Cox H, Johnson MR, Pozniak A, Pelly M, Orton CM, Bhavsar PK.   +18 more
europepmc   +1 more source

Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment. [PDF]

BMJ Open
Hikida S, Nomoto H, Uemura Y, Suzuki T, Izumikawa K, Ohge H, Yamato M, Kato Y, Hase R, Aoyagi T, Hagiya H, Nukui Y, Yamamoto K, Takesue Y, Sawada K, Shimizu Y, Miyamoto S, Tamura N, Takahashi K, Saito S, Miyazaki K, Morino E, Tokita D, Ohmagari N.   +23 more
europepmc   +1 more source

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing. [PDF]

J Antimicrob Chemother
Petit PR, Touret F, Driouich JS, Paré A, de Lamballerie X, Marlin R, Contreras V, Relouzat F, Gallouët AS, Pascal Q, Guedj J, Le Grand R, Nougairède A, Solas C.   +13 more
europepmc   +1 more source

Population Pharmacokinetic Analysis and Modelling of Serum Uric Acid Dynamics in Patients Treated with Favipiravir. [PDF]

Pharmaceuticals (Basel)
Yamada T, Kawasuji H, Ogami C, Hasegawa C, Kaneda M, Yamaguchi D, Iida S, Aoyama T, Yamamoto Y, Tsuji Y.   +9 more
europepmc   +1 more source

Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. [PDF]

Nat Med
Erameh C, Okwaraeke K, Kleist C, Edeawe O, Adedosu N, Ekata E, Abejegah C, Owhin S, Babatunde F, Omansen T, Meneguim A, Duvignaud A, Mischlinger J, Ithete N, Oestereich L, Hinzmann J, Ahmed L, Duraffour S, Eifedyi R, Okogbenin S, Akhideno P, Ayodeji OO, Günther S, Wicha SG, Jaspard M, Pahlmann M, Ramharter M, Groger M.   +27 more
europepmc   +1 more source